PAM
BCRX icon

Premier Asset Management’s BioCryst Pharmaceuticals BCRX Stock Holding History

Premier Asset Management’s Portfolio BCRX Stock Details BCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-192,765
Closed -$730K – 119
2019
Q2 		$730K Buy
+192,765
New +$1.16M 0.17% 77

Other funds holding BCRX

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
VMI
VHCP Management II New York $379M AUM 421.62% 1-Year Est. Return

Premier Asset Management's BCRX Position: Q3 2019 in Review

Premier Asset Management sold out of BioCryst Pharmaceuticals (BCRX) in Q3 2019, closing a stake of 192,765 shares — an estimated $730K sold.

Premier Asset Management first reported a position in BCRX in Q2 2019 and held it in 1 quarter. The position peaked at $730K in Q2 2019. 115 funds tracked by Wall St. Rank hold BCRX as of Q3 2019.

  • Premier Asset Management reported no remaining BioCryst Pharmaceuticals position as of Q3 2019 after selling out during the quarter.
  • Premier Asset Management sold 192,765 BioCryst Pharmaceuticals shares in Q3 2019, an estimated $730K.
  • Premier Asset Management first reported a position in BioCryst Pharmaceuticals in Q2 2019 and held it in 1 quarter.
  • Premier Asset Management's BioCryst Pharmaceuticals position peaked at $730K in Q2 2019.
  • 115 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q3 2019.

Based on Premier Asset Management's 13F filing for Q3 2019, filed 1 Nov 2019.